Itraconazole/Kleva

Itraconazole, the active ingredient in Itraconazole/Kleva, is a triazole antifungal presented as an oral formulation for systemic and topical fungal infections. It is used to treat a range of mycotic diseases in adult patients, including skin, nail and deep organ infections caused by susceptible fungi. The drug is administered under medical supervision and requires appropriate diagnostic confirmation.

GNH USA supplies Itraconazole/Kleva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable access to quality‑assured products across multiple regions.

Itraconazole is indicated for a variety of fungal infections affecting the skin, nails and internal organs.

- Dermatophyte infections: effective in treating skin infections caused by dermatophyte fungi. - Onychomycosis: clears fungal nail disease and promotes regrowth of healthy nail tissue. - Blastomycosis: used to eradicate systemic Blastomyces dermatitidis infection. - Histoplasmosis: treats disseminated Histoplasma capsulatum disease. - Coccidioidomycosis: manages pulmonary and extrapulmonary Coccidioides infection. - Aspergillosis: employed in therapy of invasive Aspergillus species infections.

Adverse reactions may occur with itraconazole therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: intermittent discomfort in the upper abdomen. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Cardiac failure: new or worsening congestive heart failure, especially in patients with pre‑existing cardiac disease.

Before initiating therapy, several safety considerations are recommended.

- Liver function monitoring: assess hepatic enzymes before and during treatment. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Cardiac assessment: avoid use in patients with known heart failure. - Pregnancy and lactation: prescribe only when benefits outweigh potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Itraconazole has a notable interaction profile that requires careful management.

Major Interactions (Avoid): - Rifampin: strong enzyme inducer that markedly reduces itraconazole plasma levels. - Ketoconazole: additive hepatotoxic potential when combined.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may increase itraconazole exposure, requiring dose adjustment. - Statins (e.g., simvastatin): increased risk of myopathy; consider alternative lipid‑lowering agents or dose modification.